CNBC
23 Jul 2026, 10:45 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
Eli Lilly will now file for approval of its next-generation obesity drug, retatrutide, in the first quarter of 2027. — This represents a significant delay from the previously stated timeline of filing as early as this year, postponing potential revenue growth.
-0.60Retatrutide demonstrated weight loss of 20.8% to 22.6% in late-stage trials for adults with obesity and complications like diabetes and cardiovascular disease. — Strong clinical efficacy in high-risk populations reinforces the drug's potential as a superior, high-value treatment.
+0.50Eli Lilly intends to seek global approval for retatrutide to treat obesity, knee osteoarthritis pain, and obstructive sleep apnea. — Expanding the indicated use cases beyond obesity increases the total addressable market and long-term revenue potential.
+0.40Continue reading
6 related stories
Search tags
The company attributed the filing delay to the need for more time to verify manufacturing and quality-control data. — While common in pharma, delays due to manufacturing/quality data can signal operational hurdles or regulatory scrutiny.
-0.20Which stocks this story touches
Positive results from five late-stage trials for retatrutide show significant weight loss and cardiovascular benefits, despite a delay in the filing timeline.
The article positions Eli Lilly's new drug as a critical tool to maintain market share majority over Novo Nordisk in the obesity market.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
WSJ
1h ago
